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Abstract
Aims
This study aimed to analyse health related quality of life (HRQoL) for patients with different
atrial fibrillation (AF) types and to identify patient characteristics, symptoms and comorbidi-
ties that influence HRQoL.
Methods
We used baseline data from the Swiss Atrial Fibrillation (Swiss-AF) study, a prospective
multicentre observational cohort study conducted in 13 clinical centres in Switzerland.
Between April 2014 and August 2017, 2415 AF patients were recruited. Patients were
included in this analysis if they had baseline HRQoL data as assessed with EQ-5D-based
utilities and visual analogue scale (VAS) scores. Patient characteristics and HRQoL were
described stratified by AF type. The impact of symptoms, comorbidities and socio-economic
factors on HRQoL was analysed using multivariable regression analysis.
Results
Based on 2412 patients with available baseline HRQoL data, the lowest unadjusted mean
HRQoL was found in patients with permanent AF regardless of whether measured with utili-
ties (paroxysmal: 0.83, persistent: 0.84, permanent: 0.80, p<0.001) or VAS score (paroxys-
mal: 73.6, persistent: 72.8, permanent: 69.2, p<0.001). In multivariable analysis of utilities
PLOS ONE | https://doi.org/10.1371/journal.pone.0226730 December 23, 2019 1 / 14
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Witassek F, Springer A, Adam L,
Aeschbacher S, Beer JH, Blum S, et al. (2019)
Health-related quality of life in patients with atrial
fibrillation: The role of symptoms, comorbidities,
and the type of atrial fibrillation. PLoS ONE 14(12):
e0226730. https://doi.org/10.1371/journal.
pone.0226730
Editor: Luigi Sciarra, Policlinico Casilino, ITALY
Received: August 7, 2019
Accepted: December 4, 2019
Published: December 23, 2019
Copyright: © 2019 Witassek et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The patient consent
forms, as approved by the responsible ethics
committee (Ethikkommission Nordwest- und
Zentralschweiz), do not allow the data to be made
publicly available. The participants signed a
consent form, which states that their data,
containing personal and medical information, are
exclusively available for research institutions in an
anonymized form. Researchers interested in
obtaining the data for research purposes can
contact the Swiss-AF lead referring to the ‘EQ-5D
baseline minimal dataset’. Contact information is
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
13
77
57
 
| 
do
wn
lo
ad
ed
: 
27
.1
.2
02
0
and VAS scores, higher European Heart Rhythm Association (EHRA) score, recurrent falls
and several comorbidities showed a strong negative impact on HRQoL while AF type was
no longer associated with HRQoL.
Conclusions
Multiple factors turned out to influence HRQoL in AF patients. After controlling for several
comorbidities, the EHRA score was one of the strongest predictors independent of AF type.
The results may be valuable for better patient assessment and provide a reference point for
further QoL and health economic analyses in AF populations.
Introduction
Atrial fibrillation (AF), the most common cardiac arrhythmia with an estimated prevalence of
2% in the general adult population of Europe [1], is associated with a broad range of symptoms
such as palpitations, dyspnoea, chest tightness, lethargy, sleeping difficulties, and psychosocial
distress [2]. In addition to the burden of the disease itself, patients with AF face an increased
risk for major complications such as heart failure, cognitive impairment, and stroke [3]. All
these factors may, depending on their grade of manifestation, impact the health-related quality
of life (HRQoL) of AF patients.
Previous studies investigating the impact of AF on HRQoL found poorer HRQoL in AF patients
compared to the general population [4–6]. However, other studies demonstrated that comorbid
conditions were more strongly related with HRQoL than the clinical manifestations of AF itself [7,
8], and that HRQoL was mainly impaired in newly diagnosed patients and rose to a normal level
with standard treatment [7]. A further study showed that HRQoL was significantly impacted by
AF type and symptoms in addition to comorbidities, regardless of disease duration [9].
AF is classified as paroxysmal (i.e., self-terminating AF lasting<7 days that does not require
cardioversion), persistent (i.e., AF sustained�7 days and/or requiring cardioversion) or per-
manent (i.e., cardioversion has failed or not been attempted) [10]. Patient characteristics usu-
ally differ by AF type, with permanent AF patients being older and showing more
comorbidities [11]. AF symptom burden, on the other hand, is often higher in paroxysmal or
persistent AF according to previous studies [2, 12]. HRQoL may thus differ depending on the
impact and strength of symptoms and comorbidities. Whether AF type itself plays an indepen-
dent role in HRQoL is not clear. The few available studies of differences in HRQoL across AF
types found either no independent difference [13] or lower HRQoL for paroxysmal and per-
manent AF [9].
Given these inconsistent findings, we aimed to investigate whether and how HRQoL varies
between AF types, to examine which patient characteristics, symptoms and comorbidities are
mainly influencing HRQoL, and to investigate whether the influence of certain symptoms or
comorbidities on HRQoL is more pronounced within specific AF types.
Materials and methods
Data source
Swiss-AF is a prospective multicentre observational cohort study conducted in 13 clinical cen-
tres in Switzerland with the aim to provide new insights on structural and functional brain
damage in patients with AF and to investigate other AF-related complications and burden, col-
lecting a large variety of clinical, genetic, phenotypic and health economic data [14, 15].
Health-related quality of life in patients with atrial fibrillation
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Recruitment started in April 2014 and was completed in August 2017. Patients were
enrolled if they were at least 65 years old. An additional subgroup of 200 patients aged between
45–65 years was enrolled as an additional aim of the cohort was to assess socio-economic
aspects of AF in the working population. Participants had to have documented paroxysmal AF
(at least twice within the last 60 months), persistent AF (documented within the last 60 months
by ECG or rhythm monitoring devices) or permanent AF. The detailed study set-up has previ-
ously been described [14]. The study protocol has been approved by the Ethics Committees of
Northwest and Central Switzerland (EKNZ), and an informed written consent was obtained
from each participant.
Patients were included in this analysis if they had baseline data on HRQoL assessed with
the three-level version of the EQ-5D (EQ-5D-3L). The EQ-5D-3L is a standardized instrument to
assess generic HRQoL and contains questions on five dimensions: mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression. For each of the five dimension, respondents are
offered three response categories (no problems, some problems, extreme problems), leading to
243 possible health states [16, 17]. These health states are then converted into index based values
(utilities) ranging from 0 to 1 by applying a country-specific valuation algorithm. As no Swiss
value set is available, we used the European Value set (VAS validated) to calculate utilities [18].
Additionally, the instrument includes a visual analogue scale (VAS), on which the patient is
asked to score his/her current health state between 0 (worst imaginable health state) and 100
(best imaginable health state).
In addition to single symptoms, such as palpitations, fatigue, or dizziness, we integrated the
European Heart Rhythm Association (EHRA) classification score into the analysis. The EHRA
score describes the severity of AF-related symptoms, specifically during the time when the
patient feels to be in the arrhythmia, and distinguishes four classes: “No symptoms” (I), “mild
symptoms” (II), “severe symptoms” (III), and “disabling symptoms” (IV) [19].
EHRA scores, symptoms, comorbidities and the questionnaire part of the EQ-5D-3L
instrument were assessed by the study personnel during patient interviews. If relevant, medical
records were additionally consulted. The VAS part of the EQ-5D-3L instrument was com-
pleted directly by the patients if possible.
Statistical analysis
Baseline characteristics, symptoms, EHRA score and HRQoL results (i.e., EQ-5D utilities and
VAS scores) are presented stratified by AF type. Discrete variables are reported as frequencies
and percentages and continuous variables as means and standard deviations. To gain an initial
understanding of differences between AF types standard univariable tests were used (Pearson
chi-square test or the Fisher’s exact test, Analysis of Variance (ANOVA)). To visualize the rela-
tive importance of comorbidities according to AF type, a grouped bar chart of proportional
occurrence is shown. Additionally, we analysed how the observed utilities or VAS scores are
associated with the EHRA score. Boxplots were used to visually describe the association
between the EHRA score and HRQoL measurements. The Kruskal-Wallis test and Spearman’s
correlation coefficients were used to test for HRQoL differences between EHRA classes.
Covariate influences on HRQoL were subsequently assessed using linear mixed-effects
models with random intercepts for centre to take into account possible effects related to the
different study centres. Possible covariates were selected based on literature review and clinical
experience. To pre-assess candidate covariates representing symptoms, comorbidities, AF
type, ECG at study visit and treatments as antiarrhythmic drugs, devices and previous pulmo-
nary vein isolation (PVI) procedures, standard univariable analyses of associations with utili-
ties or VAS scores were performed. Covariates were considered for a multivariable model if
Health-related quality of life in patients with atrial fibrillation
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they showed a p-value < 0.2 in the univariable analysis. In the multivariable analysis, covari-
ates with a p-value higher than 0.2 were excluded from the model. Collinearity was not
observed during analysis. Clinical observations by the study team led to a notion that the
impact of comorbidities on HRQoL might be more pronounced in permanent AF patients
than in paroxysmal or persistent AF patients while symptoms might be stronger predictors in
patients with paroxysmal or persistent AF. In order to assess this assumption, multiplicative
interactions between AF type and symptoms or comorbidities were tested and included in the
final model if they were statistically significant and lowered the Bayesian information criterion
(BIC). The BIC is a criterion for model selection and implies a penalisation for over-complex-
ity. A decrease in BIC indicates an improvement in model fit and better predictive ability [20].
To account for an expected ceiling effect at the value 1 for the utility values, we complemented
the linear regression with a Tobit regression, often used to modelling censored variables in
econometrics research [21].
All analyses were performed using STATA 13.1 and a p-value <0.05 was considered as
threshold for statistical significance.
Results
Patients and symptom burden
Of the 2415 patients enrolled in the study, 2412 (99.9%) completed the baseline EQ-5D and
were included in this analysis. The mean age was 73.2 years (IQR 68; 79) and 72.6% of the
patients were male. AF type at baseline was paroxysmal for 1079 (44.7%) patients, persistent
for 709 (29.4%) and permanent for 624 (25.9%). Patients with permanent AF were older and
had higher rates of comorbidities as compared to patients with paroxysmal or persistent AF
(Table 1 and S1 Table). For all three AF types, the most frequent comorbidities were hyperten-
sion and heart failure (Fig 1). The patients with persistent AF showed the highest use of antiar-
rhythmic drugs at baseline. The prevalence of previous PVI was similar in paroxysmal and
persistent AF and significantly lower in permanent AF.
AF-related symptoms were more frequent in paroxysmal and persistent AF than in perma-
nent AF. Consistent with this observation, symptom severity, as measured by the EHRA score,
was higher for paroxysmal and persistent AF. Across all three AF types, more than 50% of the
patients were in EHRA class I and hence free of AF-related symptoms (Table 2).
Quality of life by AF type
The lowest unadjusted average HRQoL was found in the permanent AF group, regardless of
whether measured with EQ-5D questionnaire results converted to utilities (paroxysmal: 0.83,
persistent: 0.84, permanent: 0.80, p<0.001) or the VAS score (paroxysmal: 73.60, persistent:
72.78, permanent: 69.17, p<0.001). Women had lower utilities and VAS scores than men,
across all three AF types (Table 3).
After correcting for age, gender, comorbidities, EHRA score, and education, AF type was
no longer associated with utilities (joint p-value = 0.054) (Table 4) or VAS scores (joint p-
value = 0.634) (Table 5). However, based on the VAS scores, the presence of AF or atrial flutter
at the baseline visit showed an independent, significant impact on HRQoL (-1.776, p = 0.045).
The EHRA score as a marker of HRQoL
Fig 2 shows unadjusted utilities and VAS scores by EHRA score across all patients. Between-
group differences according to the Kruskal-Wallis test were significant for both (p<0.001).
Spearman’s correlation coefficients also indicated decreased HRQoL with increasing EHRA
Health-related quality of life in patients with atrial fibrillation
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score (utilities: r = -0.13, p<0.001; VAS score: r = -0.12, p<0.001). However, differences
between medians were more pronounced in the VAS scores. There was no difference between
EHRA classes 3 and 4, with EHRA class 4 represented only by 45 patients.
The impact of symptoms and comorbidities on HRQoL
Multivariable analysis additionally indicated that several symptoms and comorbidities were
independently associated with HRQoL. The strongest independent predictors of lower utility
Table 1. Baseline characteristics according to AF type. BMI, body mass index; NOACs, new oral anticoagulants; MoCA, Montreal Cognitive Assessment.
Paroxysmal Persistent Permanent p
N (%) 1079 (44.7) 709 (29.4) 624 (25.9)
Age mean (SD) 72.5 (8.6) 71.8 (8.5) 76.3 (7.4) <0.001
Age groups <0.001
<65 n/N (%) 143/1079 (13.3) 109/709 (15.4) 34/624 (5.4)
65-<75 n/N (%) 480/1079 (44.5) 329/709 (46.4) 216/624 (34.6)
75-<85 n/N (%) 389/1079 (36.1) 235/709 (33.1) 291/624 (46.6)
> = 85 n/N (%) 67/1079 (6.2) 36/709 (5.1) 83/624 (13.3)
Male n/N (%) 737/1079 (68.3) 531/709 (74.9) 484/624 (77.6) <0.001
BMI mean (SD) 27.3 (4.9) 27.9 (4.7) 28.1 (4.6) 0.001
Time since first diagnosis (years) mean (SD)
range
4.9 (5.9)
0–52.8
5.1 (7.3)
0–55.7
9.6 (9.5)
0–63.8
<0.001
Antiarrhythmics at baseline n/N (%) 272/1079 (25.2) 228/708 (32.2) 164/623 (26.3) 0.004
Oral Anticoagulation at baseline <0.001
NOACs n/N (%) 614/1078 (57.0) 416/709 (58.7) 199/624 (31.9)
Vitamin K antagonists n/N (%) 318/1078 (29.5) 245/709 (34.6) 388/624 (62.2)
none n/N (%) 146/1078 (13.5) 48/709 (6.8) 37/624 (5.9)
History of PVI n/N (%) 270/1079 (25.0) 177/709 (25.0) 41/624 (6.6) <0.001
Device (PM, CRT, CRT-ICD, ICD, loop recorder) n/N (%) 209/1079 (19.4) 118/709 (16.6) 153/624 (24.5) 0.001
MoCA Score mean (SD)
range
25.1 (3.2)
10–30
25.1 (3.2)
9–30
24.2 (3.4)
7–30
<0.001
AF or Flutter at study visit (ECG) n/N (%) 180/1071 (16.8) 292/705 (41.4) 588/624 (94.2) <0.001
https://doi.org/10.1371/journal.pone.0226730.t001
Fig 1. Frequencies of comorbidities according to AF type. TIA, transient ischemic attack; DVT, deep vein
thrombosis; OSAS, obstructive sleep apnoea syndrome; PAD, peripheral artery disease.
https://doi.org/10.1371/journal.pone.0226730.g001
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were higher EHRA class (-0.042 for class 3; -0.069 for EHRA class 4, joint p-value = 0.001),
recurrent falls (-0.065, p<0.001) and history of pulmonary embolism/deep vein thrombosis
(DVT) (-0.052, p<0.001). Further significant negative predictors were presence of malignant
disease, sleep apnoea, peripheral artery disease (PAD), hypertension, diabetes and renal insuf-
ficiency. Lower education and symptoms of dizziness were also associated with lower utility.
Effects of chest pain and fatigue trended towards lower utility (Table 4). If the EHRA score was
tentatively excluded from the model these effects became significant. The ECG during the
baseline visit and treatment variables representing the use of antiarrhythmic drugs, history of
PVI and implanted device showed no impact and were excluded from the final model.
Table 2. Symptoms and EHRA Score according to AF type. EHRA, European Heart Rhythm Association.
Paroxysmal Persistent Permanent p
Symptoms related to AF
Palpation n/N (%) 511/1076 (47.5) 224/709 (31.6) 134/624 (21.5) <0.001
Dizziness n/N (%) 194/1076 (18.0) 94/709 (13.3) 53/624 (8.5) <0.001
Chest pain n/N (%) 134/1076 (12.5) 50/709 (7.1) 52/624 (8.3) <0.001
Exercise intolerance n/N (%) 245/1076 (22.8) 206/709 (29.1) 87/624 (13.9) <0.001
Dyspnea n/N (%) 239/1076 (22.2) 202/709 (28.5) 148/624 (23.7) 0.009
Fatigue n/N (%) 183/1076(17.0) 133/709 (18.8) 70/624 (11.2) <0.001
Syncopes n/N (%) 47/1076 (4.4) 16/709 (2.3) 15/624 (2.4) 0.019
None n/N (%) 312/1076(29.0) 270/709 (38.1) 336/624 (53.8) <0.001
EHRA Score 0.001
I n/N (%) 606/1078 (56.2) 390/709 (55.0) 410/624 (65.7)
II n/N (%) 365/1078 (33.8) 237/709 (33.4) 170/624 (27.2)
III n/N (%) 83/1078 (7.7) 68/709 (9.6) 37/624 (5.9)
IV n/N (%) 24/1078 (2.2) 14/709 (2.0) 7/624 (1.1)
>II n/N (%) 107/1078 (9.9) 82/709 (11.6) 44/624 (7.1) 0.019
https://doi.org/10.1371/journal.pone.0226730.t002
Table 3. EQ-5D-EU-Utilities and VAS Scores according to AF type.
All Paroxysmal Persistent Permanent p
All:
Health Utility EU Mean (SD) 0.82 (0.17) 0.83 (0.17) 0.84 (0.17) 0.80 (0.18) <0.001
Range 0.12–1.00 0.04–1.00 0.00–1.00
VAS Score Mean (SD) 72.20 (17.48) 73.60 (17.24) 72.78 (17.74) 69.17 (17.27) <0.001
Range 3.00–100.00 0.00–100.00 5.00–100.00
Male:
Health Utility EU Mean (SD) 0.85 (0.17)�� 0.85 (0.16)� 0.82 (0.17)�� <0.001
Range 0.14–1.00 0.24–1.00 0.00–1.00
VAS Score Mean (SD) 74.86 (17.12)�� 73.36 (17.70) 69.99 (17.02)� <0.001
Range 3.00–100.00 0.00–100.00 25.00–100.00
Female:
Health Utility EU Mean (SD) 0.78 (0.18)�� 0.82 (0.19)� 0.76 (0.19)�� 0.016
Range 0.12–1.00 0.04–1.00 0.08–1.00
VAS Score Mean (SD) 70.81 (17.19)�� 71.03 (17.77) 66.32 (17.88)� 0.024
Range 8.00–100.00 0.00–100.00 5.00–100.00
��p<0.001 and
�p<0.05 between male and female.
https://doi.org/10.1371/journal.pone.0226730.t003
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The strongest independent predictor of lower VAS scores was again higher EHRA class
(-2.594 for class 2; -6.557 for class 3; joint p-value<0.001). Other than in the model of utility,
history of pulmonary embolism/DVT played only a minor role but history of malignant dis-
ease (-5.243, p<0.001) was one of the strongest predictors for HRQoL. Further significant pre-
dictors of lower VAS scores were chest pain, recurrent falls, sleep apnoea, PAD, hypertension,
diabetes, heart failure, renal insufficiency, myocardial infarction, stroke and lower education
(Table 5). In this model also, use of antiarrhythmic drugs and implanted device showed no
impact on HRQoL and were thus excluded. AF or atrial flutter during study visit showed a sig-
nificant negative impact on HRQoL while previous PVI did not yield any effect in the final
model.
Testing of interaction effects between AF type and symptoms and comorbidities, respec-
tively, indicated that sleep apnoea had a negative effect on utilities in paroxysmal and perma-
nent AF but not in persistent AF (p for interaction = 0.049). The negative effect of chest pain
seemed to be more pronounced in persistent AF as compared to the other two AF types when
Table 4. Multivariable regression analysis: Predictors of utility in AF patients. Joint p values: AF type p = 0.054, age p<0.001, EHRA Score p = 0.001, Education level
p = 0.004. Study centre was included as a random effect variable in the model. OSAS, obstructive sleep apnoea syndrome; PAD, peripheral artery disease; DVT, deep vein
thrombosis; EHRA, European Heart Rhythm Association.
EQ-5D utility
Coef. p-value 95% CI
AF type (paroxysmal as reference)
persistent 0.008 0.340 -0.008 0.023
permanent -0.014 0.092 -0.031 0.002
Age groups (<65 as reference)
65-<75 0.012 0.284 -0.009 0.034
75-<85 -0.012 0.288 -0.035 0.010
> = 85 -0.049 0.002 -0.082 -0.018
Female -0.039 <0.001 -0.054 -0.023
Dizziness -0.022 0.027 -0.041 -0.002
Chest pain -0.022 0.057 -0.044 0.001
Fatigue -0.016 0.086 -0.035 0.002
Recurrent falls -0.065 <0.001 -0.089 -0.041
Malignant disease -0.021 0.019 -0.039 -0.003
OSAS -0.028 0.003 -0.046 -0.009
PAD -0.034 0.006 -0.058 -0.009
Hypertension -0.024 0.001 -0.039 -0.009
Diabetes -0.031 0.001 -0.050 -0.013
Heart failure -0.012 0.137 -0.028 -0.004
Renal insufficiency -0.026 0.002 -0.044 -0.009
History of pulmonary embolism/DVT -0.052 <0.001 -0.075 -0.030
History of stroke -0.017 0.082 -0.036 0.002
EHRA Score (1 as reference)
EHRA Score 2 -0.014 0.071 -0.029 0.001
EHRA Score 3 -0.042 0.002 -0.068 -0.016
EHRA Score 4 -0.069 0.006 -0.118 -0.019
Educational level (basic as reference)
middle 0.016 0.151 -0.006 0.037
advanced 0.034 0.003 0.011 0.056
Constant 0.930 <0.001 0.892 0.970
https://doi.org/10.1371/journal.pone.0226730.t004
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measuring HRQoL with the VAS Score (p for interaction = 0.015). Also, PAD showed a nega-
tive effect on VAS scores in paroxysmal and persistent AF but a positive effect in permanent
AF (p for interaction = 0.012). According to the BIC criterion, the interaction terms did not
improve model fit and predictive ability. Hence, they were not included in the main models
represented in Tables 4 and 5 but shown in [Online Appendix].
The results of the Tobit regressions were fully consistent with those of the linear regression
(details not shown).
Discussion
This cross-sectional analysis of 2412 AF patients indicated that HRQoL was mainly influenced
by symptom severity and comorbidities, but not independently by the type of AF. We had
expected that type of AF might impact QoL not only due to immediate symptom burden but
Table 5. Multivariable regression analysis: Predictors of the VAS score in AF patients. Joint p values: AF type p = 0.634, age p<0.001, EHRA Score p<0.001, Education
level p = 0.010. Study centre was included as random effect in the model. OSAS, obstructive sleep apnoea syndrome; PAD, peripheral artery disease; DVT, deep vein
thrombosis; TIA, transient ischemic attack; EHRA, European Heart Rhythm Association; PVI, pulmonary vein isolation.
VAS Score
Coef. p-value 95% CI
AF type (paroxysmal as reference)
persistent -0.601 0.464 -2.208 1.006
permanent -0.933 0.380 -3.016 1.151
Age groups (<65 as reference)
65-<75 1.922 0.084 -0.261 4.106
75-<85 -0.428 0.719 -2.763 1.907
> = 85 -2.555 0.121 -5.787 0.676
Female -2.527 0.002 -4.118 -0.936
Chest pain -4.009 <0.001 -6.220 -1.799
Fatigue -1.664 0.078 -3.518 0.189
Recurrent falls -3.467 0.005 -5.865 -1.068
Malignant disease -5.243 <0.001 -7.012 -3.474
OSAS -2.848 0.003 -4.710 -0.986
PAD -3.104 0.013 -5.554 -0.655
Hypertension -1.999 0.007 -3.463 -0.536
Diabetes -3.039 0.001 -4.850 -1.227
Heart failure -3.297 <0.001 -4.899 -1.694
Renal insufficiency -3.528 <0.001 -5.231 -1.825
History of pulmonary embolism/DVT -1.942 0.092 -4.202 0.319
History of myocardial infarction -3.510 <0.001 -5.335 -1.686
History of stroke -3.865 <0.001 -5.789 -1.940
AF/Flutter at study visit -1.776 0.045 -3.515 -0.037
Previous PVI 1.770 0.052 -0.012 3.552
EHRA Score (1 as reference)
EHRA Score 2 -2.594 0.001 -4.081 -1.107
EHRA Score 3 -6.557 <0.001 -9.122 -3.993
EHRA Score 4 -4.872 0.050 -9.737 -0.006
Educational level (basic as reference)
middle 3.146 0.004 1.012 5.280
advanced 3.304 0.004 1.056 5.552
Constant 82.099 <0.001 78.177 86.019
https://doi.org/10.1371/journal.pone.0226730.t005
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also due to factors such as the frequency of symptoms, related fear of symptoms occurring, or
habituation in case of permanent AF. However, or results did not show this. VAS scores were
negatively influenced if the patient had AF or atrial flutter in the baseline ECG during the
study visit.
We had expected that the impact of comorbidities on HRQoL might be more pronounced
in permanent AF patients than in paroxysmal or persistent AF patients and that on the other
hand, symptom severity might be a stronger predictor in patients with paroxysmal or persis-
tent AF. However, after testing for interactions we found only interactions with no obvious
clinical interpretation and could therefore not confirm such a relationship.
In general, when analysing HRQoL data, it is important to not only consider the statistical
significance of effects but also their clinical relevance. This is usually achieved using the con-
cept of minimal clinically important difference, which describes whether or not observed
changes are meaningful to patients [22]. Although we found several significant predictors of
HRQoL, the effects of all single predictors were below the minimal clinically important differ-
ence, if defined as a half standard deviation [23]. Applied to the present study, this would be
equivalent to changes of 0.09 for the utilities and of 8.74 for the VAS scores, respectively.
Fig 2. Boxplots of utility and VAS score according to the EHRA class.
https://doi.org/10.1371/journal.pone.0226730.g002
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However, many patients in our sample were affected by several predictors of reduced HRQoL.
Such combinations may have led to clinically important reductions of HRQoL in some patients,
as reflected by distribution of values in the histograms of utilities and VAS scores shown in Fig 3.
Previous studies also reported different patient and disease characteristics to be associated
with HRQoL in AF patients [24]. Concerning comorbidities, previous studies mentioned sleep
apnoea [24, 25], PAD [25], coronary artery disease [24], diabetes [9], and previous stroke [9]
as important predictors, which is in line with our results. Heart failure, mentioned also by pre-
vious studies [24, 25], was only significant in our VAS score model but not in the utility
model. Interestingly, also hypertension remained significantly associated with HRQoL in both
models, although it is often not directly felt by the patients. One additional, interesting obser-
vation in our study was the strong impact of recurrent falls. This underlines the importance of
risk/history of falls assessment in the decision making on medical therapies for AF patients
[26]. This notion is consistent with previous observations. For example, in a survey where 41
member centres of the European Heart Rhythm Association EP Research Network completed
a web-based questionnaire on frailty, recurrent falls were mentioned as one of the comorbidi-
ties most frequently associated with the frailty syndrome and as one important consideration
that influences the choice of anticoagulation drug therapy [27]. To our knowledge, no previous
study showed the association of falls and HRQoL in AF patients. Interestingly, in our study,
the type of anticoagulation at baseline had no impact on HRQoL even if previous studies indi-
cated lower HRQoL in patients treated with vitamin K antagonists for stroke prevention [28]
and for venous thromboembolism [29]. This finding may be explained by the fact that we cor-
rected for several factors which may influence the medical decision on the type of the anticoa-
gulation given.
Immediate symptoms of AF such as palpations, fatigue, and syncope played only a minor
role in our multivariable models of HRQoL. However, if we excluded the EHRA score, these
symptoms became more important. Nevertheless, we decided to include the EHRA score in
the reported models, as it was a relatively strong independent predictor of HRQoL and to effi-
ciently consider the absence of symptoms in a substantial proportion of patients.
When looking at the crude association between EHRA scores and HRQoL measurements,
both VAS scores and utilities showed a negative association with EHRA class. Differences
between the HRQoL medians for each EHRA class were more pronounced in the VAS score.
This consistency between patient-reported HRQoL and the physician-assessed EHRA score
supports that the EHRA score provides relevant information on the patient’s condition in the
daily clinical praxis. Other studies which evaluated the association between EHRA score and
patient-reported HRQoL also found a good agreement between the two measures [25, 30].
Some non-modifiable, demographic factors were also associated with reduced HRQoL.
Additionally to higher age, we found that women had significantly lower HRQoL than men,
also after multivariable adjustment. The effect size of gender was comparable to that of certain
comorbidities in the utility (Table 4) and VAS score (Table 5) models. Lower HRQoL in
women was already described in previous studies investigating HRQoL in AF patients [7, 9,
24, 31]. The reasons why women frequently report lower HRQoL are not fully understood.
Higher rates of depression in women were discussed previously, as well as a different subjective
perception of HRQoL [7]. A recent study by Blum et al. showed lower health perception and a
higher symptom burden in women than men suffering from AF [2].
Strengths and limitations
The strength of the present study is the large number of patients included, and that we could
consider a wide variety of possible determinant factors including socioeconomic factors such
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as education. Given only 0.1% missing baseline EQ-5D questionnaires, the results reflect the
study population very well. However, the majority of patients enrolled in this cohort is over 65
years old and the study population may therefore not be representative of the full population
of AF patients in Switzerland. This could affect mean HRQoL values. Additionally, the study
includes mainly Caucasian patients and the results may not be generalizable to other popula-
tions. Although the differentiation between AF types is well defined theoretically, allocation in
clinical practice is sometimes difficult and misclassifications may occur. Furthermore, to esti-
mate EQ-5D utilities, we had to use the European value set as no value set for Switzerland is
available. The observation of higher average values and more patients reporting perfect
HRQoL in the questionnaire-based utility part compared to the VAS part of the EQ-5D is
expected. Given the design of the instrument, EQ-5D utilities are only responsive to relatively
severe impairments of HRQoL [32]. We did not use a disease-specific questionnaire to mea-
sure HRQoL, due to two major advantages of the EQ-5D instrument, namely inter-disease
comparability and usability for health economic analysis.
Fig 3. Distribution of utility and VAS score in the study population.
https://doi.org/10.1371/journal.pone.0226730.g003
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Conclusion
In conclusion, the results showed that the EHRA score is a good marker of HRQoL in AF
patients, and that comorbidities have a greater impact on HRQoL than the type of AF. The
study provides some relevant details on the multifactorial character of HRQoL in AF patients.
This is important not only for better patient assessment in clinical practice, but also for further
studies addressing HRQoL in AF patients, including health economic evaluations. Specifically,
our findings provide a starting point for further, longitudinal studies of the development of
HRQoL of the Swiss-AF patient cohort, where follow-up data continue to be collected. From a
health-economic perspective, improving HRQoL may stimulate a decrease in the need for
active health care, which may in turn decrease the financial burden of public healthcare, thus
contributing to improve and keep up high-quality treatment of AF.
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